Senior management

Gunilla Osswald
Gunilla Osswald
Chief Executive Officer

In the current position since 2014, employed since 2013. More than 30 years’ experience from drug development. Successfully brought projects from pre-clinical and clinical development to regulatory approval and market introduction as well as managed in- and outlicensing of drug projects. Leading positions at Astra/AstraZeneca during 1985-2013, including Vice President with the responsibility of the product portfolio in neurodegenerative diseases

Born: 1961
Education: Pharmacist 1983 and Ph.D. in biopharmacy and pharmacokinetics at Uppsala University 1984, Sweden
Other current assignments: Board member of PledPharma AB (publ) and SpineMedical AB and deputy board member of LPB Sweden AB
Prior assignments (past five years): Board member of SP Process Development AB, SpineMedical Sverige AB and LPB Sweden Holding AB
Holdings: 33,800 B-shares and call options entitling to the acquisition of 66,270 B-shares

Jan Mattsson
Jan Mattsson
Vice President Finance, Chief Financial Officer

In current position since 2017. More than 30 years’ experience in business and administration, including CFO for Sefina Finance AB, Allenex AB, Argnor Wireless Ventures AB, Logitall AB and Investment AB Kinnevik

Born: 1960
Education: MBA, University of Örebro, Sweden, 1984
Other current assignments: –
Prior assignments (past five years): Board member of Sefina Svensk Pantbelåning AB and Humidus AB
Holdings: 33,000 B-shares (privately and through Almsäter Interim Management AB) and call options entitling to the acquisition of 9,270 B-shares

Gunilla Andersson
Gunilla Andersson
Senior Director HR

In the current position since January 2019. Contracted since 2014 for HR. The first two years for various HR related assignments and from 2016 for the role as HR Director. Nearly 30 years’ experience as HR consultant and HR manager from educational organizations and pharmaceutical companies like Pharmacia and Novartis among others. For the past 17 years, she has managed her own consulting company focusing on HR, leadership and recruitment

Born: 1961
Education: B.Sc. Human Resource Development and Labour Relations from Lund University 1990, Sweden
Other current assignments: –
Prior assignments (past five years): –
Holdings: –

Hans Basun
Hans Basun
Vice President Clinical Development, Chief Medical Officer

In the current position since 2007. More than 20 years’ experience from the pharmaceutical industry in leading position in clinical research at Astra Arcus/AstraZeneca. Background as Senior Consultant at Huddinge University Hospital and Uppsala University Hospital, Sweden

Born: 1949
Education: Medical degree and residency in psychiatry and geriatrics, Associate Professor at Karolinska Institutet and Adjunct Professor at Uppsala University
Other current assignments: Deputy board member of SpineMedical AB
Prior assignments (past five years): –
Holdings: 48,093 B-shares

Johanna Fälting
Johanna Fälting
Vice President Translational Science & Pharmacology

In current position since January 2018, employed since 2012. 18 years’ experience of neuroscience/pharmacology, translational science and development in the global pharma and biotech industry

Born: 1972
Education: Ph.D. in Physiology, Stockholm University 2001; Licentiate degree in physiology, Stockholm University 1997; Master’s degree in biology, Stockholm University 1995, Sweden
Other current assignments: Deputy board member of Biozoul AB
Prior assignments (past five years): –
Holdings: 23,050 B-shares and call options entitling to the acquisition of 14,220 B-shares

Lars Lannfelt
Lars Lannfelt
Senior Vice President University Collaborations

Co-opted member of the Senior Management Team. In current position since September 2018. Founder of BioArctic with Pär Gellerfors in 2003. Board member and a number of assignments and roles in the company since then. More than 35 years’ experience from research in Alzheimer´s disease and other neurodegenerative diseases. Professor of Geriatrics at Uppsala University 2001; Senior Professor at Uppsala University 2016 and member of the Royal Swedish Academy of Sciences since 2004

Born: 1949
Education: Medical degree 1978; specialist in psychiatry 1987; doctoral thesis at Karolinska Institutet 1990; Associate Professor of Neurogenetics at Karolinska Institutet 1993; specialist in geriatrics 2000, Sweden
Other assignments: Board member of BioArctic AB, Demban AB and LPB Sweden AB
Prior assignments (past five years): Board member of Demban Förvaltning AB, SpineMedical Sverige AB, SpineMedical AB and LPB Sweden Holding AB
Holdings: 8,639,998 A-shares and 22,723,707 B-shares through Demban AB

Mikael Moge
Mikael Moge
Vice President Chemistry, Manufacturing & Control and Protein Chemistry

In current position since January 2018, employed since 2012. 20 years’ experience from drug development and 15 years’ experience as research and development manager within process development and GMP manufacturing. Previously section manager at Process R&D at AstraZeneca

Born: 1967
Education: Master of Engineering chemical engineering, KTH Royal Institute of Technology 1992, Ph.D. of Science organic chemistry, KTH 1997, Stockholm, Sweden
Other current assignments: –
Prior assignments (past five years): –
Holdings: Call options entitling to the acquisition of 6,825 B-shares

Christer Möller
Christer Möller
Vice President Pre-Clinical Development, Chief Scientific Officer

In the current position since 2006. 20 years’ experience from developing protein drugs from idea to clinical trials including leading positions at small biotech/pharma companies; Zymenex A/S among others. In addition, comprehensive academic experience having pursued research projects concerning growth factors and preclinical research in diabetes

Born: 1959
Education: B.Sc in Biology Stockholm University 1983; Ph.D. in Medical Science, Karolinska Institutet 1992, Sweden
Other current assignments: –
Prior assignments (past five years): –
Holdings: 35,505 B-shares and call options entitling to the acquisition of 8,265 B-shares

Nora Sjödin
Nora Sjödin
Vice President Regulatory Affairs

In the current position since January 2018, employed in 2017. 25 years’ experience from leading positions in global Regulatory Affairs in companies such as AstraZeneca, NDA Regulatory Service and Pharmalink. The extensive regulatory affairs experience includes regulatory matters from early development projects to approved pharmaceuticals on the market

Born: 1957
Education: General Nursing, SRN, 1978, B.Sc. 1982, Sweden
Other current assignments: –
Prior assignments (past five years): –
Holdings: 2,000 B-shares